On March 31, 2022 Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, reported the details of its presence at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, which will be held April 8-13, 2022, both in person in New Orleans, US and virtually (Press release, Biognosys, MAR 31, 2022, View Source [SID1234611314]). The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery and TrueTarget. Additionally, Biognosys contributed to a poster that will be presented by its collaborator, NeoGenomics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The proteome contains a wealth of information about health and disease, and mass spectrometry-based proteomics has great potential in uncovering that information," commented Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys. "Our AACR (Free AACR Whitepaper) data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome. We illustrate how we’ve been able to increase efficiency and scalability at every step of the process. Moreover, we’re showcasing data we’ve generated with our collaborators that demonstrate the practical application of our platforms across all stages of research and drug development, from discovery to clinical settings."
Biognosys will also be present with a team of scientific experts at booth #885.
Talk Details
Abstract 2136: Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach
Presenter: Yuehan Feng, Ph.D.
Collaborator: Cedilla Therapeutics
Platform, Technology and Application: TrueTarget, High Resolution Limited Proteolysis Mass Spectrometry (HR-LiP), Drug Target Validation
Session: Drug Design and Lead Optimization Strategies Toward Novel or Difficult-to-Drug Cancer Targets
Date and Time: Monday, April 11, 3:20 p.m. – 3:35 p.m. CDT
Poster Presentation Details
Abstract 1374: Discovery of MHC class I and class II neoantigens in lung cancer in needle biopsy tissue samples using an optimized high-throughput workflow
Presenter: Marco Tognetti, Ph.D.
Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Immunopeptidome Profiling
Session: Tumor Antigens, Antigen Presentation, and Tumor Immunity
Date and Time: Monday, April 11, 9:00 a.m. – 12:30 p.m. CDT
Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis
Presenter: Yuehan Feng, Ph.D.
Collaborator: Crown Bioscience
Platform, Technology, and Application: TrueDiscovery, Hyper Reaction Monitoring, Phosphoproteome Profiling
Session: Patient-Derived Xenografts
Date and Time: Tuesday, April 12, 1:30 p.m. – 5:00 p.m. CDT
Abstract 2924: Target identification, selectivity profiling and mechanistic insights of a CDK9 inhibitor using complementary proteomics methods
Presenter: Yuehan Feng, Ph.D.
Collaborator: AstraZeneca plc
Platform, Technology and Application: TrueTarget, Limited Proteolysis Mass Spectrometry (LiP-MS), Drug Target Deconvolution
Session: Structural and Chemical Biology
Date and Time: Tuesday, April 12, 9:00 a.m. – 12:30 p.m. CDT
Abstract 3923: Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
Presenter: Jakob Vowinckel, Ph.D.
Collaborator: NeoGenomics Laboratories
Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
Session: Proteomics, Signaling Networks, and Biomarker Discovery
Date and Time: Wednesday, April 13, 9:00 a.m. – 12:30 p.m. CDT
Abstract 3920: Precise solid tumor classification through unbiased quantification of proteoforms deep into tissue leakage
Presenter: Marco Tognetti, Ph.D.
Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Biofluid Biomarker Discovery
Session: Proteomics, Signaling Networks, and Biomarker Discovery
Date and Time: Wednesday, April 13, 9:00 a.m. – 12:30 p.m. CDT
NeoGenomics Poster Collaboration Details
Abstract 1267: Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
NeoGenomics Presenter: Anna Juncker-Jensen, Ph.D.
Biognosys co-authors: Nigel Beaton, Ph.D.; Kristina Beeler, Ph.D. Tobias Treiber, Ph.D.; Jakob Vowinckel, Ph.D.
Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
Session: Biomarkers Predictive of Therapeutic Benefit 2
Date and Time: Monday, April 11, 9:00 a.m. – 12:30 p.m. CDT
For the most up to date information and resources about Biognosys’ presence at AACR (Free AACR Whitepaper), visit biognosys.com/accr22.
About TrueDiscovery
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.
About TrueTarget
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys.
TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio